OBJECTIVE: HydroCoil (MicroVention, Aliso Viejo, CA), a hydrogel-platinum coil hybrid device, is one of various efforts to overcome delayed recanalization of coiled intracranial aneurysms. The purpose of this study was to investigate the outcome of intracranial aneurysms treated with HydroCoils. METHODS: This multicenter prospective study included 80 aneurysms in 76 patients treated with HydroCoils. There were 32 (40%) ruptured and 48 (60%) unruptured aneurysms; 22 (28%) were large aneurysms (maximal diameter, Ն10 mm) and 58 (72%) were small. Aneurysm volumes were 100 mm 3 or more in 48 (60%) and less than 100 mm 3 in 32 (40%); in 13 aneurysms (16%), volumes were 600 mm 3 or more. Efficacy and safety were evaluated on the basis of degree of initial occlusion, procedure-related complications, and the follow-up result. RESULTS: Initial aneurysmal occlusion was complete in 60 (75%) aneurysms and near-complete in 14 (17.5%). Procedure-related complications included aseptic meningitis-related problems, including delayed hydrocephalus in 13 patients (28% among cases of unruptured aneurysms) and thromboembolism in two patients. Radiological follow-up data obtained 6 months or more after coil embolization were available in 54 aneurysms (68%) and revealed stable occlusion in 48 (89%) aneurysms, minor recanalization in one (2%), and major recanalization in five (9%). All of the recanalized aneurysms were 600 mm 3 or more in volume, and aneurysm volume was a single important variable related to delayed recanalization on multiple logistic regression analysis (P ϭ 0.016). CONCLUSION: HydroCoil embolization seems to be a feasible treatment option in intracranial aneurysms in terms of initial aneurysmal occlusion rate and durability at the time of the follow-up evaluation; however, caution is required regarding aseptic meningitis and delayed hydrocephalus. Calculated aneurysmal volume of 600 mm 3 seems to be critical in determining the anatomic outcome in aneurysms embolized with HydroCoils.
D
elayed aneurysmal recanalization has been addressed as one of major limitations of coil embolization in the treatment of intracranial aneurysms since its introduction (5) . Repeat treatment of recanalized aneurysms will carry additional burden for the patients and require additional cost. To overcome this limitation, various modified coils have been developed and are commercially available, including some polyglycolic acid/lactide copolymer (PGLA)-coated coils (Matrix [Boston Scientific/Target, Fremont, CA], Cerecyte [Micrus Endovascular, San Jose, CA], and Nexus coils [Micro Therapeutics, Irvine, CA]) and a hydrogel-coated coil (HydroCoil; MicroVention, Aliso Viejo, CA). The purpose of this study was to investigate safety and efficacy of HydroCoils in the treatment of intracranial aneurysms.
PATIENTS AND METHODS

Study Design
In this prospective multicenter observational study, patients treated with HydroCoils for intracranial aneurysms were registered to an independent central core laboratory during the period from April 2005 to March 2006. The primary endpoint was major aneurysmal recanalization on follow-up angiography (conventional or magnetic resonance angiography) 6 months after treatment or intracranial bleeding related to the treated aneurysm during the follow-up period. The inclusion criteria were as follows: 1) ruptured or unruptured intracranial aneurysm, 2) maximal aneurysmal diameter of 5 to 15 mm, 3) Hunt and Hess Grade 0 to III, and 4) percent length of HydroCoils detached (i.e., total length of HydroCoils inserted into an aneurysm/total length of coils inserted into an aneurysm x 100) of 50% or more. The exclusion criteria included: 1) repeat embolization for recanalized or recurrent aneurysms; 2) stent-assisted coil embolization; 3) embolization with other coated coils; 4) complex-shaped (or severely multilobulated) aneurysms; 5) thrombosed aneurysms; 6) fusiform, infectious, traumatic, or dissecting aneurysms; and 7) patients undergoing arterial occlusion with coils.
A reviewer (HSK) at the independent core laboratory scrutinized the data regarding the registered cases and decided whether or not the patients met the inclusion criteria and did not display features of the exclusion criteria. Clinical and radiological follow-up data submitted to the core laboratory were critically reviewed.
Patient Population
A total of 80 aneurysms in 76 patients were treated with HydroCoils at five institutions and were registered in the core laboratory. Under close scrutiny, 51 aneurysms in 50 patients met the inclusion criteria and displayed none of the exclusion criteria. Reasons for violation included a length of Hydrocoils less than 50% in 11 patients, poor Hunt-Hess grade in nine patients, aneurysm size smaller than 5 mm in five patients, aneurysm size larger than 15 mm in three patients, stent placement during the coil embolization in three patients, and repeat coil embolization in one patient. Three patients displayed more than one exclusion criteria. On the basis of the intent-to-treat principle, patients violating the criteria described previously in the core laboratory review were included in this analysis.
There were 48 (60%) unruptured and 32 (40%) ruptured aneurysms; 58 (72%) were small (maximal diameter, Ͻ10 mm) and 22 (28%) were large (maximal diameter, Ն10 mm). The average aneurysm diameter, or the arithmetic mean of diameters in three perpendicular axes, was less than 10 mm in 62 (77%) aneurysms and 10 mm or larger in 18. The size of the aneurysm neck was more than 3 mm in 62 (78%) and 3 mm or less in 18. The maximal sac diameter to neck size ratio was more than 1.5 in 65 (81%) patients and 1.5 or less in 15. The patients are summarized in Table 1 .
Calculation of Aneurysm Volume, Coil Volume, and Packing Attenuations
Aneurysm volume was calculated based on the assumption that aneurysms are ellipsoid. The following formula was applied: aneurysm volume ϭ 4π (height/2) (length/2) (width/2)/3 (3). Each diameter in three perpendicular axes was measured from three-dimensional (3D) angiographic images, if available. Otherwise, it was approximated from two radio-opaque markers. The values (x, y, and z in two perpendicular planes) were expressed in millimeters (one digit below point). Coil volume was calculated assuming that a coil is a cylinder with a diameter of the primary coil and was derived from the following formula: coil volume ϭ π (diameter/2) 2 (length). Calculated packing attenuation was defined as the ratio of the volume of the deployed coils to the aneurysm volume. For HydroCoils, we used the outer diameter of the coil after expansion of the hydrogel material, provided by the company, i.e. 0.022, 0.027, and 0.034 inches for HydroCoil embolization system-10, HydroCoil embolization system-14, and HydroCoil embolization system-18, respectively. For other bare platinum coils, the outer diameters of the coils were used for calculation as provided by the corresponding manufacturers.
Endovascular Procedures
Endovascular coil embolization was performed following a standardized protocol in the neuroangiography suite, as described previously (8) (9) (10) (11) . In most cases, general anesthesia was induced. Systemic anticoagulation with heparin was used from the beginning of the procedures in unruptured cases but only after protective packing with coils in patients with recent hemorrhage. Heparin was administered intravenously just after the introducer sheath was inserted, first as a 3000-U bolus followed by 1000 U/hour. In general, heparin was administered to achieve an activated clotting time approximately twice that of normal.
The one or two coils deployed for the initial coil basket could be a HydroCoil or a bare platinum coil. Then, HydroCoils were preferentially deployed until attenuated packing was achieved without compromising the parent arterial lumen. Bare platinum coils could be deployed during or at the end of coil packing at the operator's discretion. HydroCoils were soaked in warm saline until shaped into the expected diameter before introduction into the microcatheter.
The aneurysm was considered completely occluded when the sac and the neck were densely packed, near-completely occluded when the sac was packed but a small neck remained, and incompletely occluded in case of a persistently opacified sac (9) . 
Criteria for Aseptic Meningitis
Diagnosis of proven aseptic meningitis was denoted when the patient showed clinical symptoms and/or signs of meningitis and cerebrospinal fluid pleocytosis but negative culture studies or when the patient developed delayed hydrocephalus. Diagnosis of presumed aseptic meningitis was denoted when the patient showed clinical symptoms and/or signs but results of cerebrospinal study were unavailable and there was no evidence of delayed hydrocephalus.
Follow-up Protocol
Conventional angiography, preferably, or magnetic resonance angiography (MRA) with 3D reconstruction was performed 6 months or more after treatment. Follow-up angiograms were obtained with an effort to recapitulate the working angles during the previous procedure based on bony landmarks. MRA examinations were performed on a Sigma 1.5-T magnetic resonance imaging unit (General Electric, Milwaukee, WI) or a Magnetom vision 1.5-T magnetic resonance imaging unit (Siemens, Erlangen, Germany) using a head coil. The MRA scans were obtained using the 3D time of flight MRA technique. The imaging parameters used were as follows: repetition time, 24 to 35; echo time, 6.9 to 7.2; flip angle, 20; section thickness, 1 to 1.5 mm; field of view, 210 ϫ 210 or 125 ϫ 177; matrix, 200 ϫ 512 or 384 ϫ 256. Plain radiography could be performed at any time during the follow-up period as necessary. Minor aneurysmal recanalization was defined as minimal coil compaction at the aneurysmal neck; major recanalization was defined as contrast filling within the aneurysm dome or significant coil loosening or compaction (8, 9) . If there was a neck remnant at the end of the original procedure and this persisted at the time of followup with no increment, it was classified as stable occlusion rather than recanalization.
Statistical Analysis
One-way analysis of variance, Mann-Whitney tests, unpaired Student's t tests, Kruskal-Wallis tests, Fisher's exact tests, χ 2 test for trend, and linear regression analysis were performed with GraphPad InStat (version 3.05 for Windows 95/NT; GraphPad Software, San Diego, CA). Multiple logistic regression analysis was performed to find factors related to aneurysmal recanalization using SPSS (version 13.0 for Windows; SPSS, Chicago, IL). Variables with P values less than 0.25 in the univariate simple logistic regression analysis were chosen as the variables for multiple logistic regression analysis. A P value of less than 0.05 was considered significant.
RESULTS
For the following analyses, dimensions of intracranial aneurysms were classified in two ways: large or small and less than 100 mm 3 , 100 to 600 mm 3 , or more than 600 mm 3 (14) .
Aneurysmal Occlusion and Packing Attenuation with HydroCoils
The degree of aneurysmal occlusion at the end of coil embolization was complete in 60 (75%) aneurysms, near-complete in 14 (17.5%), and incomplete in six (7.5%). Percent length of HydroCoils ranged from 31 to 81% (mean Ϯ standard deviation, 58.8 Ϯ 10.8). No aneurysms were embolized solely with HydroCoils. Calculated packing attenuation ranged from 37 to 117% (mean Ϯ standard deviation, 69.0 Ϯ 16.1). Packing attenuations according to the degree of aneurysmal occlusion, size of aneurysms, volume of aneurysms, and percent length of HydroCoils are shown in Tables 2 to 4. The more complete the degree of occlusion, the higher the packing attenuation ( Table 2 ). The packing attenuation was significantly higher in cases of complete occlusion and small aneurysms compared with those of incomplete occlusion and large aneurysms (Tables 2 and 3) . Cases in which the aneurysm volume was larger than 600 mm 3 attained significantly lower packing attenuation compared with those in which aneurysm volume was less than 100 mm 3 (P ϭ 0.0053) or 100 to 600 mm 3 (P ϭ 0.0062) ( Table 4) . Finally, when the percent length of HydroCoils was 50% or more, the calculated packing attenuation was significantly higher (71.2 Ϯ14.7% versus 48.8 Ϯ14.9; P Ͻ 0.0001).
There was a linear relationship between aneurysm volumes and coil volumes (Fig. 1) 
Procedure-related Events
Procedural and periprocedural complications included aseptic meningitis-related problems in 13 patients, thromboembolism in two patients, and coil loop herniation requiring rescue by stent in one patient. There were no cases of procedure-related mortality. Of 13 cases of proven (n ϭ 9) or presumed (n ϭ 4) aseptic meningitis, six patients developed hydrocephalus and four underwent shunt surgery ( Fig. 3; Table 5 ). Three of these patients were reported previously (6) . In the others, symptoms were alleviated with (n ϭ 3) or without (n ϭ 4) steroid medication over the course of several days. Cerebrospinal fluid examinations demonstrated pleocytosis (32/mm 3 -3800/mm 3 ) with elevated protein but normal glucose levels. Differential cell counts demonstrated dominancy of polymorphonuclear leukocytes during the second to third day after embolization and dominancy of lymphocytes on the 13 th day. All culture studies revealed negative results.
Radiological Follow-up Results
There were no cases of subsequent bleeding during the follow-up period after coil embolization. Radiological follow-up data obtained 6 months or more after coil embolization were available for 54 aneurysms (12 mo or more for 13 aneurysms) and revealed stable occlusion in 48 (89%) aneurysms, minor recanalization in one (2%), and major recanalization in five (9%). All of the recanalized aneurysms were large and more than 600 mm 3 in volume ( Table 6 ). For these aneurysms, calculated packing attenuation ranged from 39 to 68%; percent length of HydroCoils ranged from 46 to 74%. Notably, there were no cases of aneurysmal recanalization when the aneurysmal volume was less than 600 mm 3 (Fig. 2) . Among various factors, aneurysm sac and neck sizes, aneurysm volume, degree of aneurysmal occlusion, and packing attenuation were associated with aneurysmal recanalization in univariate analysis ( Table 7) . Presentation (ruptured or unruptured), maximal sac diameter to neck size ratio, aneurysm location (anterior or posterior circulation), and percent length of HydroCoils were not related to delayed aneurysmal recanalization. Multiple logistic regression analysis revealed that aneurysm volume was the only significant factor related to aneurysmal recanalization (P ϭ 0.016).
DISCUSSION
Our study showed efficacy of HydroCoils in the treatment of intracranial aneurysms; however, concerns for aseptic meningitis and delayed hydrocephalus were raised. Of 46 patients with unruptured aneurysms treated with HydroCoils, 13 (28%) developed aseptic meningitis-related problems (Table 5) . Thus, 
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caution might be required in this regard. Female sex and internal cerebral artery location were predominant in this subpopulation of patients. Aneurysm sizes were variable, and aneurysm volume ranged from 21 to 2720 mm 3 (mean Ϯ standard deviaton, 496 Ϯ 720 mm 3 ). Six patents, corresponding to 13% among those with unruptured aneurysms, showed delayed hydrocephalus; four symptomatic patients underwent shunt operations. Post-embolization meningitis could able to be controlled by corticosteroid administration or conservative management. However, post-meningitic delayed communicating hydrocephalus was thought to be a serious procedurerelated complication, especially when this was symptomatic and required shunt surgery. In our series, four patients had typical symptoms of communicating hydrocephalus (urinary incontinence, gait disturbance and/or severe memory impairment). All the clinical problems were resolved after ventriculoperitoneal shunt surgery. The mechanism of aseptic meningitis is still unknown. Hydrogel, a cross-linked copolymer of acrylamide and sodium acrylate, is claimed to be inert material. A report regarding histological examinations in a rabbit model revealed only minimal inflammatory reaction without evidence of egress of hydrogel through the aneurysm walls (7). Meyers et al. (12) reported two cases of chemical meningitis which had been treated with PGLA-coated coils as well as HydroCoils. Cases of delayed symptomatic hydrocephalus have been reported after coil embolization with Hydrocoils for unruptured aneurysms in another institution (1, 2) . It has also been reported that hydrocephalus was developed in three (5.6%) out of 54 patients with unruptured aneurysms. Considering that there were no cases of meningitis or hydrocephalus after treatment with PGLA-coated coils (9), these unusual phenomena would be HydroCoilrelated. The role of the coils, clot burden, aneurysm size, thrombin and cytokines in developing meningitis and hydrocephalus, and efficiency of steroids to prevent them still remain to be answered. Further research into problems related to aseptic meningitis or hydrocephalus should be undertaken.
In this series, HydroCoils showed superb ability in achieving high packing attenuation with mean packing attenuation of 69% (range, 38-117%). Thus, less amount of thrombus was expected to remain within the aneurysm upon completion of embolization with HydroCoils. In a report, mean packing attenuation was 30.9% (range, 11-73%) in cases of PGLA-coated coil embolization and 21.4% (range, 9-51%) in cases embolized with bare platinum coils (9) . In linear regression analysis, as shown in Figure 1 , the slope (0.9213; 95% confidence interval, 0.9117; 0.9310) of the HydroCoil group was higher than those of PGLA-coated coils (0.7223; 95% confidence interval, 0.7064; 0.7383) and bare platinum coils (0.6451; 95% confidence interval, 0.6296; 0.6605) reported previously (9) , which means that higher volumes of coils could be deployed in the same volumes of aneurysms with HydroCoils. Table 8 summarizes coated ("bioactive") coil experiences with follow-up results reported in the literature. The major recanalization rates range from 9 to 21%. In comparison with the previous report (9), the overall major recanalization rate of 9% in Hydrocoil series was not significantly different from that of bare platinum coil series or PGLA-coated coil series. It was notable that there were no cases of recanalization in this series when the aneurysm volume was less than 600 mm 3 (corresponding to a spherical aneurysm with a diameter of 10.5 mm) and W e congratulate the authors on their multicenter observational study of embolization of intracranial aneurysms using HydroCoils. In this study, five centers enrolled 76 patients with 80 aneurysms (32 aneurysms were ruptured and 48 were unruptured). There was no control group. All aneurysms were 5 to 15 mm in size, and no adjunctive techniques could be utilized. The authors report that aneurysm volume of greater than 600 mm 3 was a single important variable related to delayed recanalization (P = 0.016). Aseptic meningitis (proven or presumed) was observed in 13 patients, and hydrocephalus was observed in six (four required ventriculoperitoneal shunting).
There are several limitations to this study, the most significant of which is the lack of long-term angiographic and clinical follow-up data. Only 54 out of 80 aneurysms (68%) had follow-up imaging at 6 months or later. Digital subtraction angiography was also not performed in all of the patients on follow-up. It is unclear what happened to the remaining 26 aneurysms.
The issue of hydrocephalus and aseptic meningitis is important. The authors report that 13 patients had proven (n = 9) or presumed (n = 4) aseptic meningitis. The presumed meningitis cases did not have lumbar puncture and diagnosis was made on clinical grounds alone. None of these four patients developed hydrocephalus. Without including these four patients, nine out of 76 patients (11.8%) developed symptoms of aseptic meningitis.
Finally, there is no control group in this study. Because of this, it is unclear what effect HydroCoils had on recanalization. Also, the likelihood of HydroCoils to cause aseptic meningitis and subsequent delayed hydrocephalus cannot be determined without a control group. This is a well constructed observational study. We agree with the authors' conclusions that HydroCoils are a feasible option for intracranial aneurysms and that caution is required for aseptic meningitis and delayed hydrocephalus. We believe the head-to-head prospective, blinded, randomized trial, HydroCoil Endovascular Aneurysm Occlusion and Packing Study, will define the efficacy and safety of HydroCoil and go a long way in determining its future use.
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